• Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics – Fighting Autoimmune Diseases
Ahead Therapeutics - Fighting Autoimmune Diseases
 
  • Home
  • The Company
    • Company Overview
    • Team
  • Technology
    • Technology Overview
    • Publications
  • Pipeline
  • Strategic Alliances
    • Science & Technical Collaborations
    • Investors & Financing
    • Partnerships
    • Patient Association
  • News & Media
    • In the News
  • Contact Us
Ahead Therapeutics - Fighting Autoimmune Diseases
Home Technology

Technology

Technology Overview


Our approach, based on Nano-technology, has allowed us to develop a powerful and highly specific pharmacological platform designed to treat and cure Auto-immune diseases. In this type of disorder, one’s own immune system mistakenly attacks one’s own cells or tissue. Depending on the specific tissue attacked, a different disease is developed: Celiac disease, Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis and Psoriasis, to mention only a few of more than 100 recognized Auto-immune diseases.

PS Liposome Structure
PS Liposome Structure

To re-establish immune tolerance against self-tissues, AHEAD THERAPEUTICS S.L. has developed a technology based on bio-mimicking Efferocytosis, a crucial and well-known physiological process involved in ‘Antigen Specific Immune Tolerance Induction’, whereby apoptotic cells are removed from the body by being recognized, recruited and engulfed by immature dendritic cells (DCs).

Our technological platform contains a wide range of Liposomes based on Phosphatidylserine and other endogenous mammal compounds. These Liposomes are of a certain particle size and are accurately produced to encapsulate a specific Auto-antigen, depending on the illness to be treated.

By administering our Liposomes with Phosphatidylserine in the outer membrane, Apoptosis in cells is simulated to trigger the Efferocytosis mechanism and generate not only Specific Tolerance against the encapsulated Auto-antigen but also to induce immunological memory.

Furthermore, as our approach is not HLA dependent, personalized treatment is not required, adding a major economical advantage to the platform.

 

 

Publications

Significant references related to Ahead Therapeutics SL.

Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes
Villalba A, et al.
Artif Cell Nanomed Biotech. (2020) 48 (1):77-83. PMID: 31852325

 

Impaired phagocytosis in dendritic cells from pediatric patients with type 1 diabetes does not hamper their tolerogenic potential
Rodriguez-Fernandez S, et al.
Frontiers in Immunology (2019) 10:2811. PMID: 31849983

 

Phosphatidylserine-liposomes Promote Tolerogenic Features on Dendritic cells in human Type 1 Diabetes by apoptotic Mimicry
Rodriguez-Fernández, et al.,
Frontiers in Immunology (2018) 9:253

 

Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis
Pujol-Autonell et al.,
Nanomedicine (Lond.) (2017) 12(11), 1231–1242

 

Use of Autoantigen-Loaded Phosphatidylserine-Liposomes to Arrest Autoimmunity in Type 1 Diabetes
Pujol-Autonell et al.,
PLOS ONE (2015) 10(6):e0127057

 

How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review
Vives Pi, Marta et al.,
Apoptosis (2015), 20 (3):263-72

 

What potential is there for liposomal-based nanotherapy for the treatment of Type 1 diabetes?
Pujol-Autonell et al.,
Nanomedicine (Lond.) (2015) 10(19), 2955–2958

 

PCT Patent (WO2015107240)

Our Company

Our Company
Privacy Policy
Terms and Conditions

Contents

Technology
Pipeline
Investors & Financing
Scientific & Technical Collaborations
Partnerships
Scientific Publications
News & Media

Latest News & Press Releases

  • Ahead Therapeutics will participate in the 4TH Antigen-specific immune tolerance summit -2021- 26-28 January
  • Ahead Therapeutics attended BIO-EUROPE 2020 last October
  • UB – Ahead Therapeutics collaboration to advance the development of analytical methods for Ahead’s technology platform.

Contact AHEAD THERAPEUTICS

AHEAD THERAPEUTICS S.L.
Parc de Recerca Edificio Eureka
(Universitat Autónoma de Barcelona)
08193 Cerdanyola del Vallès

Email
 
Back to Top

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837515
Copyright AHEAD THERAPEUTICS S.L. 2018-2019 All rights reserved. Permissions must be obtained explicitly.
Design MOD by IDYMA Websolutions (Barcelona) .